- Home
- GBR vs APVO Comparison
GBR vs APVO Comparison
Compare GBR & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- APVO
- Stock Information
- Founded
- GBR 1978
- APVO 2016
- Country
- GBR United States
- APVO United States
- Employees
- GBR N/A
- APVO N/A
- Industry
- GBR Oil & Gas Production
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- APVO Health Care
- Exchange
- GBR Nasdaq
- APVO Nasdaq
- Market Cap
- GBR 5.2M
- APVO 4.9M
- IPO Year
- GBR N/A
- APVO N/A
- Fundamental
- Price
- GBR $1.20
- APVO $1.57
- Analyst Decision
- GBR
- APVO Strong Buy
- Analyst Count
- GBR 0
- APVO 1
- Target Price
- GBR N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- GBR 269.3K
- APVO 176.9K
- Earning Date
- GBR 11-12-2025
- APVO 11-06-2025
- Dividend Yield
- GBR N/A
- APVO N/A
- EPS Growth
- GBR N/A
- APVO N/A
- EPS
- GBR N/A
- APVO N/A
- Revenue
- GBR $151,000.00
- APVO N/A
- Revenue This Year
- GBR N/A
- APVO N/A
- Revenue Next Year
- GBR N/A
- APVO N/A
- P/E Ratio
- GBR N/A
- APVO N/A
- Revenue Growth
- GBR 4.14
- APVO N/A
- 52 Week Low
- GBR $0.67
- APVO $1.41
- 52 Week High
- GBR $1.78
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- GBR 65.63
- APVO 47.04
- Support Level
- GBR $0.95
- APVO N/A
- Resistance Level
- GBR $1.26
- APVO $1.54
- Average True Range (ATR)
- GBR 0.10
- APVO 0.18
- MACD
- GBR 0.03
- APVO -0.02
- Stochastic Oscillator
- GBR 84.98
- APVO 57.55
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.